Gilead Moves Deeper Into Oral Immunology With PepStar Buyout
Gilead Sciences is paying about $1.275 billion upfront for global rights to an experimental oral peptide from PepStar Therapeutics, a move that widens its push into inflammation and raises the stakes in the race to build non-injectable options for inflammatory bowel disease. The lead asset, HCXT-2001, is designed to inhibit the IL-23 receptor, a biologically validated target already reached by several approved immunology drugs. The difference here is route: instead of the chronic injections that have long defined this class, Gilead is betting that peptide engineering can turn a historically fragile molecule into an oral therapy.
A single sentence captures the commercial logic. If the molecule can survive the gut and reach its target, it could challenge one of the field’s most durable assumptions about how biologics and peptide drugs must be delivered.
Why an Oral IL-23 Program Matters in IBD
IL-23 sits near the center of mucosal immune signaling in ulcerative colitis and Crohn’s disease, where persistent immune activation drives tissue injury, symptom burden, and repeated treatment escalation. Current IL-23-targeting therapies have changed care, but most are antibodies given by injection. That creates a practical barrier for long-term adherence, especially in diseases that already demand frequent monitoring, dose changes, and layered immunosuppression.
An oral agent aimed at the same pathway could alter the treatment sequence before patients ever reach an injectable biologic. It would not replace the biology of IL-23 blockade; it would change the patient experience around it. For chronic diseases like IBD, that matters because route of administration often shapes persistence on therapy as much as efficacy does.
HCXT-2001 is a macrocyclic peptide, a structure that loops the amino acid chain into a ring. That design is not cosmetic. Peptides ordinarily break down in the digestive tract and struggle to cross intestinal barriers, which is why they are usually given by injection. The macrocyclic format is intended to protect the molecule from digestive enzymes and improve intestinal absorption, creating a plausible path to oral dosing without abandoning the drug class entirely.
Gilead’s Pipeline Strategy Favors Earlier-Stage Inflammation Assets
Gilead’s leadership has signaled for months that inflammation is becoming a central growth area, but the company is approaching it differently from oncology. In a January briefing, chief executive Daniel O’Day described inflammation as a longer-term build, with a focus on earlier-stage assets rather than the late-stage depth that Gilead has sought in cancer.
This acquisition fits that blueprint. HCXT-2001 is in Phase 1 testing, and no clinical data have been disclosed so far. The deal is therefore less about near-term revenue than about securing a differentiated platform before competitors lock up the field. Gilead also said the program could be developed as a standalone treatment or paired with other agents, a sign that the company sees combination therapy as part of the value proposition from the outset.
One obvious partner is emvistegrast, Gilead’s internally discovered oral small molecule in development for IBD. The drug inhibits alpha 4 beta 7 integrin, a gut-directed receptor involved in intestinal inflammation, and Gilead has positioned it as a once-daily pill. Pairing a gut-homing integrin inhibitor with IL-23 receptor blockade would offer a two-pronged anti-inflammatory strategy: one pathway restrains immune cell trafficking, while the other dampens inflammatory signaling deeper in the immune cascade.
Competitive Pressure Is Already Building Around Oral Peptides
Gilead is not entering an empty field. Johnson & Johnson already has an FDA-approved oral peptide, Icotyde, that blocks IL-23 and is marketed for plaque psoriasis. J&J is also testing that agent in ulcerative colitis and Crohn’s disease, making it a direct competitive benchmark for any future oral IL-23 therapy. J&J has said Icotyde could eventually reach up to $5 billion in peak annual revenue, which makes the commercial logic for rivals easy to understand.
AbbVie, J&J, and Eli Lilly also market injectable agents that target the IL-23 axis in IBD, including Skyrizi, Tremfya, and Omvoh. J&J’s Stelara remains relevant as well, even though its patents have expired. Against that backdrop, Gilead’s bet is narrower but potentially more disruptive: if oral delivery can be paired with durable receptor coverage, the product could compete not by inventing a new pathway but by making an established one easier to use.
The Ulcerative Colitis Data Give the Program Early Credibility
The acquisition lands as Gilead is already presenting clinical data from another oral inflammation program. At the United European Gastroenterology Week meeting in Barcelona, the company reported Phase 2 results for emvistegrast in ulcerative colitis. The highest of three doses met the study’s main goal at 12 weeks.
Among patients receiving emvistegrast, 66% achieved a clinical response compared with 37% in the placebo group. Clinical remission occurred in 31% of treated patients versus 8% with placebo. Gilead said the drug was well tolerated, and the study is continuing. Those numbers do not prove success for HCXT-2001, which remains earlier in development, but they do show that Gilead is assembling an oral IBD portfolio around biologically credible targets rather than speculative mechanisms.
The clinical relevance is straightforward. If oral agents can deliver meaningful response and remission rates in IBD, they could move treatment earlier in the disease course and reduce dependence on injections that some patients delay or avoid. For a field built around chronic control, convenience is not cosmetic; it can affect whether inflammation stays suppressed long enough to matter.
Deal Terms Point to Long-Term Confidence, Not Immediate Readout Risk
The PepStar transaction includes an upfront payment of $1.275 billion, with no milestone details disclosed. Gilead and PepStar expect to close the deal by the end of the year. In practical terms, Gilead is paying for time, optionality, and a differentiated oral platform before clinical proof is available.
That leaves the most important questions unresolved. HCXT-2001 has not yet produced disclosed human efficacy or safety data, so the field still does not know whether the macrocyclic design will translate into enough exposure, enough receptor coverage, and enough tolerability to matter in IBD. The next inflection point will be actual Phase 1 data, followed by the harder test of whether oral IL-23 inhibition can hold its own against injectable antibodies and J&J’s emerging oral competitor.